This list is based on the watchlists of people on Stock Events who follow SGIOY. It's not an investment recommendation.
This list is an analysis based on recent market events. It's not an investment recommendation.
Shionogi & Co., Ltd., an Osaka, Japan-based pharmaceutical company established in 1878, focuses on the discovery, development, production, and commercialization of medicines, diagnostic tools, and medical devices primarily within Japan. The company, known as Shionogi Shoten Co., Ltd. until its rebranding in 1943, maintains a comprehensive portfolio. Its marketed products include Fetroja, an agent for multidrug-resistant gram-negative bacterial infections; Xofluza, an antiviral treatment for influenza; and Tivicay, utilized in HIV therapy. Shionogi's extensive pipeline features investigational therapies such as Symproic for opioid-induced constipation; S-120083 for inflammatory pain and S-010887 for neuropathic pain; S-117957 for insomnia; sivopixant, addressing neuropathic pain, sleep apnea syndrome, and persistent chronic cough; S-637880 for neuropathic low back pain; Zuranolone for depression; SDT-001 for attention-deficit/hyperactivity disorder; BPN14770 for Fragile X syndrome and Alzheimer's disease; and S-237648 and S-309309 for obesity. Further development initiatives encompass ADR-001 for decompensated liver cirrhosis; S-723595 for NASH; various oncology candidates including S-588410 for esophageal and bladder cancer, S-488210 for head and neck squamous cell carcinoma, S-588210 for solid tumors, S-222611 for malignant tumors, and S-531011 for solid tumors; S-770108 for idiopathic pulmonary fibrosis; SR-0379 for cutaneous ulcers; S-005151 for stroke and epidermolysis bullosa; S-0373 for spinocerebellar ataxia; and multiple compounds targeting COVID-19, such as S-600918, S-217622, and S-555739 for mitigating disease progression. Additionally, the firm offers antibody test kits for COVID-19. Shionogi fosters strategic alliances, including collaborations with Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University, aimed at advancing antimalarial drug research.
FAQs
What is Shionogi &. stock price today?▼
The current price of SGIOY is $9.64 USD — it has decreased by -4.08% in the past 24 hours. Watch Shionogi &. stock price performance more closely on the chart.
What is Shionogi &. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Shionogi &. stocks are traded under the ticker SGIOY.
Is Shionogi &. stock price growing?▼
SGIOY stock has risen by +5.46% compared to the previous week, the month change is a +9% rise, over the last year Shionogi &. has showed a +17.27% increase.
What is Shionogi &. market cap?▼
Today Shionogi &. has the market capitalization of 8.58B
When is the next Shionogi &. earnings date?▼
Shionogi &. is going to release the next earnings report on February 5, 2027.
What were Shionogi &. earnings last quarter?▼
SGIOY earnings for the last quarter are 0.16 USD per share, whereas the estimation was 0.28 USD resulting in a -41.16% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Shionogi &. revenue for the last year?▼
Shionogi &. revenue for the last year amounts to 3.27B USD.
What is Shionogi &. net income for the last year?▼
SGIOY net income for the last year is 1.34B USD.
Does Shionogi &. pay dividends?▼
Yes, SGIOY dividends are paid semi-annual. The last dividend per share was 0.12 . As of today, Dividend Yield (FWD)% is 2.22%.
How many employees does Shionogi &. have?▼
As of November 17, 2026, the company has 6,223 employees.
In which sector is Shionogi &. located?▼
Shionogi &. operates in the Health & Wellness sector.
When did Shionogi &. complete a stock split?▼
The last stock split for Shionogi &. was on October 2, 2024 with a ratio of 1.5:1.
Where is Shionogi &. headquartered?▼
Shionogi &. is headquartered in Kita, Japan.